Tag:

Vical

Latest Headlines

Latest Headlines

Biotechs angling for T-cell response in race for next-gen herpes vaccine

When Australian biotech Admedus announced Phase I results for its herpes simplex virus vaccine last week, it was far from the first company to do so. A whole new generation of vaccinemakers are trying their hand in a race that's heating up.

Vical restructures, chops 47 jobs after PhIII immunotherapy flop

Just days after Vical's shares ($VICL) were blitzed by the news that its cancer immunotherapy Allovectin was being scrapped after flunking a Phase III, about 40% of the company's staffers paid for the failure with their jobs.

Vical discards melanoma immunotherapy Allovectin after PhIII failure

San Diego-based Vical recruited 390 patients to test Allovectin (velimogene aliplasmid), a cancer immunotherapy that's been in the clinic for years. The biotech had been bullish about its Phase II data. The company didn't disclose any data this morning, saying that it would release results at a later scientific conference.

Vaxfectin-based malaria vaccine could stop transmission

An experimental malaria vaccine could prevent the transmission of malaria from mosquitoes to humans.

Navy moves dengue fever vaccine into clinical trials

The Naval Medical Research Center (NMRC) has started a Phase I trial of its dengue virus vaccine, developed in collaboration with Vical.

Astellas licenses Vical vax for $130M

Japan's Astellas will pay up to $130 million to license a vaccine to prevent cytomegalovirus (CMV) reactivation in transplant recipients. The disease is typically dormant in those who are healthy but

Vical, Astellas ink $130M vaccine licensing deal

Japan's Astellas will pay up to $130 million to license a vaccine to prevent cytomegalovirus (CMV) reactivation in transplant recipients. The disease is typically dormant in those who are healthy but

Live from BIO: Transitioning to human models a big obstacle for DNA cancer vaccines

WASHINGTON, D.C.-- A panel at the 2011 BIO International convention explained that the real obstacle comes when the focus turns to humans rather than animal models. As a collaborator of Inovio

Vical touts animal study of vax adjuvant

Vical announced today that the company's Vaxfectin adjuvant significantly boosted the immune response of DNA-based vaccines against a range of pathogens and cancer in preclinical models from rodents

Vical heralds regulatory approval of melanoma vax for dogs

San Diego-based Vical says that Sanofi subsidiary Merial Limited has won approval from the Department of Agriculture for a dog melanoma vaccine that Merial in-licensed from the developer. And Vical